Charles River Laboratories (CRL) Q3 2025 10-Q Quarterly Report
Filed: Nov 5, 2025Period ending Sep 27, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Charles River Laboratories (CRL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 27, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Charles River Laboratories Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Q3 revenue $1,004.9M, down 0.5% YoY from $1,009.8M; nine months revenue $3,021.2M, down 0.9% YoY from $3,047.4M
- • Operating margin Q3 13.3% vs 11.6% YoY (up 170 bps); nine months margin 10.2% vs 13.0% YoY (down 280 bps)
- • Best segment Q3: RMS revenue up 7.9% to $213.5M, operating margin 16.2% vs 13.9% YoY; worst segment Manufacturing nine months operating margin 7.6% vs 19.3% YoY (down 1,170 bps)
- • Operating cash flow nine months $590.1M, up from $575.2M YoY; capital expenditures down to $130.2M from $157.4M YoY
- • Management cites cautious client spending, DSA backlog decline, ongoing restructuring with $175M cost savings in 2025, $70M incremental savings in 2026 expected, SEC investigation ongoing, and strategic focus on acquisitions and divestitures
Risk Factors
- • No newly added risk factors this quarter; most risks carry forward from 2024 10-K without material changes
- • Most materially updated risk: Impact of U.S.-imposed tariffs on imports from Vietnam, Mauritius, China, still uncertain and affecting supply chain costs
- • Regulatory risk: FDA plans to reduce animal testing in preclinical studies using NAMs, potentially impacting demand for traditional animal research services
- • Operational risk: Lower-than-expected demand growth in 2024, leading to global restructuring actions and efficiency initiatives targeting $70M annual net cost savings
- • Financial risk: Strategic review underway with focus on acquisitions, divestitures, and capital deployment amid potential stock price volatility and business disruption
Charles River Laboratories Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.0B
▼ -0.5% YoY▼ -2.6% QoQ
Net Income
$54M
▼ -21.9% YoY▲ +4.0% QoQ
Net Margin
5.4%
▼ -148bp YoY▲ +35bp QoQ
Source: XBRL data from Charles River Laboratories Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Charles River Laboratories Quarterly Reports
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.